People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bellicum Pharmaceuticals, Inc | — | Pharmaceuticals | Series C | $136.8M | $3.3B | 2009 |
David Spencer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Spencer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dennis K. Stone | 1 | 3 |
| Thomas J. Farrell | 1 | 2 |
| James F. Brown | 1 | 2 |
| Kevin Slawin | 1 | 2 |
| David M. Spencer | 1 | 1 |
| Kevin M. Slawin | 1 | 1 |
| Thomas Farrell | 1 | 1 |
| Ken K. Moseley | 1 | 1 |
| Frank McGuyer | 1 | 1 |
| Annemarie K. Moseley | 1 | 1 |
| Joseph K. Senesac | 1 | 1 |
| Frank M. McGuyer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.